Name: Global Selective Cox-2 Inhibitors Market Insights and Forecast to 2035
Brand: Extent Research
Price: 3500 USD
Availability: InStock
Rating: 4.9 (178 reviews)

Global Selective Cox-2 Inhibitors Market

Market Size in USD Billion

CAGR : 17.60%

USD 1.14

2025

USD 4.17

2033

Forecast Period	2025 - 2033
Market Size (Base Year)	USD 1.14 Billion
Market Size (Forecast)	USD 4.17 Billion
CAGR	17.60%
Major Market Players	Data provided in full report

Extent Research has announced the release of its global Selective Cox-2 Inhibitors market report that will offer all the latest trends of the market. The report also helps briefly estimate the market size of Selective Cox-2 Inhibitors that is growing at a considerable rate in the predicted timeframe. Furthermore, the new innovations and technological developments taking place are accredited to the increasing need for this product/service worldwide.

Data provided by Extent Research. Source: https://www.extentresearch.com/selective-cox-2-inhibitors-market

The use of various research methodologies helps the report deliver all the crucial market data within this confined article. The Selective Cox-2 Inhibitors market report also covers all the vital segments of the market. The report also provides the market size and entire comprehension of the market along with outlook prospects. Moreover, the key market players of Selective Cox-2 Inhibitors include Boehringer-Ingelheim, TerSera Therapeutics, Iroko Pharmaceuticals, Apotex, Yung Shin Pharmaceutical, Breckenridge Pharmaceutical, Meda Pharmaceuticals, Cipla, Glenmark Pharmaceuticals, Teva, PuraCap Pharmaceutical, Almirall Limited, Lupin Pharmaceuticals, Aurobindo Pharma, Pfizer, Mylan, Takeda, Bayer, Novacap, Abbott, Geri-Care, Perrigo, Kopran, Merck, Hengrui pharmaceutical, Kelun Group, Qilu Pharmaceutical, Taro Pharmaceuticals , . The competitive landscape offers the complete product portfolio, revenue statistics, and company profile during the forecast timeframe. Furthermore, the complete briefing of the Selective Cox-2 Inhibitors market is covered in the market report. The research study also touches upon all the important market segmentations including product type, applications, and geographical distribution.

The report includes the various regions North America, Europe, Asia Pacific, Latin America, Middle East & Africa experiencing Selective Cox-2 Inhibitors market growth. The growth of the Selective Cox-2 Inhibitors market in these regions is basically due to the distribution channels, supply & demand chain, pricing analysis, revenue, size, and other market analytics.

Segmentation of the Global Selective Cox-2 Inhibitors Market:

By Product type

Meloxicam, Celecoxib, Etoricoxib, Imrecoxib, Etodolac, Parecoxib, Other,

by Application

Rheumatoid Arthritis, Osteoarthritis, Spondylosis Chronica Ankylopoietica, Other,

Questions answered in the report include:

What is the expected market size by the end of the forecast period?
What are the major factors initiating the global Selective Cox-2 Inhibitors market growth?
What are the latest developments and trending market strategies that are influencing the growth of the Selective Cox-2 Inhibitors market?
What are the key outcomes of the Selective Cox-2 Inhibitors market developments?
Who are the key players in the market?
What are the opportunities and challenges faced by the key players?

Report Scope and Market Segmentation

ATTRIBUTES	Global Selective Cox-2 Inhibitors Market KEY MARKET INSIGHTS
Segments Covered	By Product Type: All Products Type Includes By Application: All Application Type Includes By End User: All End User Type Includes By Distribution Channel: All Distribution Channel Includes
Countries Covered	North America U.S., Canada, Mexico Europe Germany, United Kingdom, France, Italy, Spain, Nordic Countries, Benelux Union, Rest of Europe Asia-Pacific China, India, Japan, New Zealand, South Korea, Australia, Southeast Asia, Rest of Asia Pacific Latin America Brazil, Argentina, Rest of Latin America Middle East & Africa Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa
Key Market Players	Leading Tier 1 Corporations Prominent Regional Manufacturers Emerging Market Disruptors Technology Integrators & Suppliers *Complete vendor layout of 15+ major players provided in the final report.
Market Opportunities	Market Size and Growth: Quantifying the total addressable market (TAM) and projected growth rates to assess financial viability. Customer Segmentation: Identifying target audience behaviors, pain points, and specific unfulfilled demands. Competitive Landscape: Analyzing existing competitors' strengths, weaknesses, and market share to pinpoint gaps and opportunities. Industry Trends: Mapping technological, regulatory, and economic shifts that create favorable conditions for market entry. Risk Assessment: Evaluating barriers to entry and operational challenges alongside strategic roadmaps for mitigation.
Value Added Data Infosets	In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by our expert team also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand.

Meet the Team

Julie

Author

Julie Jayne is a distinguished multidisciplinary strategist and the Head of Research at Extent Research, where she leverages over a decade of comprehensive experience in the global market intelligence industry. Backed by a robust academic foundation that includes a B.Sc. and an MBA, she perfectly...

Priya M

Reviewed By

With over 14 years of dedicated professional expertise in business-to-business (B2B) intelligence, Priya M stands as a distinguished leader in corporate strategy, revenue growth, and advanced data analysis. Her dynamic career is defined by a relentless focus on mitigating business risks and empowering corporate executives...

Learn more about Priya M

BASIC ATTRIBUTES \| KEY MARKET INSIGHTS
Report Title	Global Selective Cox-2 Inhibitors Market
Base Year	2025
Forecast Period	2025 - 2033
Market Size (Base)	USD 1.14 Billion
Projected Size	USD 4.17 Billion
CAGR	17.60%

                            1 Report Business Overview
    1.1 Study Scope
    1.2 Market Analysis by Type
        1.2.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2035
        1.2.2 Meloxicam
        1.2.3 Celecoxib
        1.2.4 Etoricoxib
        1.2.5 Imrecoxib
        1.2.6 Etodolac
        1.2.7 Parecoxib
        1.2.8 Other
    1.3 Market by Application
        1.3.1 Global Selective Cox-2 Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2035
        1.3.2 Rheumatoid Arthritis
        1.3.3 Osteoarthritis
        1.3.4 Spondylosis Chronica Ankylopoietica
        1.3.5 Other
    1.4 Study Objectives
    1.5 Years Considered
2 Global Growth Trends
    2.1 Global Selective Cox-2 Inhibitors Market Perspective (2017-2035)
    2.2 Selective Cox-2 Inhibitors Growth Trends by Region
        2.2.1 Selective Cox-2 Inhibitors Market Size by Region: 2017 VS 2021 VS 2035
        2.2.2 Selective Cox-2 Inhibitors Historic Market Size by Region (2017-2022)
        2.2.3 Selective Cox-2 Inhibitors Forecasted Market Size by Region (2023-2035)
    2.3 Selective Cox-2 Inhibitors Market Dynamics
        2.3.1 Selective Cox-2 Inhibitors Industry Trends
        2.3.2 Selective Cox-2 Inhibitors Market Drivers
        2.3.3 Selective Cox-2 Inhibitors Market Challenges
        2.3.4 Selective Cox-2 Inhibitors Market Restraints
3 Competition Landscape by Key Players
    3.1 Global Top Selective Cox-2 Inhibitors Players by Revenue
        3.1.1 Global Top Selective Cox-2 Inhibitors Players by Revenue (2017-2022)
        3.1.2 Global Selective Cox-2 Inhibitors Revenue Market Share by Players (2017-2022)
    3.2 Global Selective Cox-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    3.3 Players Covered: Ranking by Selective Cox-2 Inhibitors Revenue
    3.4 Global Selective Cox-2 Inhibitors Market Concentration Ratio
        3.4.1 Global Selective Cox-2 Inhibitors Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global Top 10 and Top 5 Companies by Selective Cox-2 Inhibitors Revenue in 2021
    3.5 Selective Cox-2 Inhibitors Key Players Head office and Area Served
    3.6 Key Players Selective Cox-2 Inhibitors Product Solution and Service
    3.7 Date of Enter into Selective Cox-2 Inhibitors Market
    3.8 Mergers & Acquisitions, Expansion Plans
4 Selective Cox-2 Inhibitors Breakdown Data by Type
    4.1 Global Selective Cox-2 Inhibitors Historic Market Size by Type (2017-2022)
    4.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Type (2023-2035)
5 Selective Cox-2 Inhibitors Breakdown Data by Application
    5.1 Global Selective Cox-2 Inhibitors Historic Market Size by Application (2017-2022)
    5.2 Global Selective Cox-2 Inhibitors Forecasted Market Size by Application (2023-2035)
6 North America
    6.1 North America Selective Cox-2 Inhibitors Market Size (2017-2035)
    6.2 North America Selective Cox-2 Inhibitors Market Size by Type
        6.2.1 North America Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        6.2.2 North America Selective Cox-2 Inhibitors Market Size by Type (2023-2035)
        6.2.3 North America Selective Cox-2 Inhibitors Market Share by Type (2017-2035)
    6.3 North America Selective Cox-2 Inhibitors Market Size by Application
        6.3.1 North America Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        6.3.2 North America Selective Cox-2 Inhibitors Market Size by Application (2023-2035)
        6.3.3 North America Selective Cox-2 Inhibitors Market Share by Application (2017-2035)
    6.4 North America Selective Cox-2 Inhibitors Market Size by Country
        6.4.1 North America Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
        6.4.2 North America Selective Cox-2 Inhibitors Market Size by Country (2023-2035)
        6.4.3 U.S.
        6.4.4 Canada
7 Europe
    7.1 Europe Selective Cox-2 Inhibitors Market Size (2017-2035)
    7.2 Europe Selective Cox-2 Inhibitors Market Size by Type
        7.2.1 Europe Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        7.2.2 Europe Selective Cox-2 Inhibitors Market Size by Type (2023-2035)
        7.2.3 Europe Selective Cox-2 Inhibitors Market Share by Type (2017-2035)
    7.3 Europe Selective Cox-2 Inhibitors Market Size by Application
        7.3.1 Europe Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        7.3.2 Europe Selective Cox-2 Inhibitors Market Size by Application (2023-2035)
        7.3.3 Europe Selective Cox-2 Inhibitors Market Share by Application (2017-2035)
    7.4 Europe Selective Cox-2 Inhibitors Market Size by Country
        7.4.1 Europe Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
        7.4.2 Europe Selective Cox-2 Inhibitors Market Size by Country (2023-2035)
        7.4.3 Germany
        7.4.4 France
        7.4.5 U.K.
        7.4.6 Italy
        7.4.7 Russia
        7.4.8 Nordic Countries
8 Asia-Pacific
    8.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size (2017-2035)
    8.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type
        8.2.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        8.2.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Type (2023-2035)
        8.2.3 Asia-Pacific Selective Cox-2 Inhibitors Market Share by Type (2017-2035)
    8.3 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application
        8.3.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        8.3.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Application (2023-2035)
        8.3.3 Asia-Pacific Selective Cox-2 Inhibitors Market Share by Application (2017-2035)
    8.4 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region
        8.4.1 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2017-2022)
        8.4.2 Asia-Pacific Selective Cox-2 Inhibitors Market Size by Region (2023-2035)
        8.4.3 China
        8.4.4 Japan
        8.4.5 South Korea
        8.4.6 Southeast Asia
        8.4.7 India
        8.4.8 Australia 
9 Latin America
    9.1 Latin America Selective Cox-2 Inhibitors Market Size (2017-2035)
    9.2 Latin America Selective Cox-2 Inhibitors Market Size by Type
        9.2.1 Latin America Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        9.2.2 Latin America Selective Cox-2 Inhibitors Market Size by Type (2023-2035)
        9.2.3 Latin America Selective Cox-2 Inhibitors Market Share by Type (2017-2035)
    9.3 Latin America Selective Cox-2 Inhibitors Market Size by Application
        9.3.1 Latin America Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        9.3.2 Latin America Selective Cox-2 Inhibitors Market Size by Application (2023-2035)
        9.3.3 Latin America Selective Cox-2 Inhibitors Market Share by Application (2017-2035)
    9.4 Latin America Selective Cox-2 Inhibitors Market Size by Country
        9.4.1 Latin America Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
        9.4.2 Latin America Selective Cox-2 Inhibitors Market Size by Country (2023-2035)
        9.4.3 Mexico
        9.4.4 Brazil
10 Middle East & Africa
    10.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size (2017-2035)
    10.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type
        10.2.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2017-2022)
        10.2.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Type (2023-2035)
        10.2.3 Middle East & Africa Selective Cox-2 Inhibitors Market Share by Type (2017-2035)
    10.3 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application
        10.3.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2017-2022)
        10.3.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Application (2023-2035)
        10.3.3 Middle East & Africa Selective Cox-2 Inhibitors Market Share by Application (2017-2035)
    10.4 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country
        10.4.1 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2017-2022)
        10.4.2 Middle East & Africa Selective Cox-2 Inhibitors Market Size by Country (2023-2035)
        10.4.3 Turkey
        10.4.4 Saudi Arabia
        10.4.5 UAE
11 Key Players Profiles
    11.1 Boehringer-Ingelheim
        11.1.1 Boehringer-Ingelheim Company Details
        11.1.2 Boehringer-Ingelheim Business Overview
        11.1.3 Boehringer-Ingelheim Selective Cox-2 Inhibitors Introduction
        11.1.4 Boehringer-Ingelheim Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.1.5 Boehringer-Ingelheim Recent Developments
    11.2 TerSera Therapeutics
        11.2.1 TerSera Therapeutics Company Details
        11.2.2 TerSera Therapeutics Business Overview
        11.2.3 TerSera Therapeutics Selective Cox-2 Inhibitors Introduction
        11.2.4 TerSera Therapeutics Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.2.5 TerSera Therapeutics Recent Developments
    11.3 Iroko Pharmaceuticals
        11.3.1 Iroko Pharmaceuticals Company Details
        11.3.2 Iroko Pharmaceuticals Business Overview
        11.3.3 Iroko Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.3.4 Iroko Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.3.5 Iroko Pharmaceuticals Recent Developments
    11.4 Apotex
        11.4.1 Apotex Company Details
        11.4.2 Apotex Business Overview
        11.4.3 Apotex Selective Cox-2 Inhibitors Introduction
        11.4.4 Apotex Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.4.5 Apotex Recent Developments
    11.5 Yung Shin Pharmaceutical
        11.5.1 Yung Shin Pharmaceutical Company Details
        11.5.2 Yung Shin Pharmaceutical Business Overview
        11.5.3 Yung Shin Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.5.4 Yung Shin Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.5.5 Yung Shin Pharmaceutical Recent Developments
    11.6 Breckenridge Pharmaceutical
        11.6.1 Breckenridge Pharmaceutical Company Details
        11.6.2 Breckenridge Pharmaceutical Business Overview
        11.6.3 Breckenridge Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.6.4 Breckenridge Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.6.5 Breckenridge Pharmaceutical Recent Developments
    11.7 Meda Pharmaceuticals
        11.7.1 Meda Pharmaceuticals Company Details
        11.7.2 Meda Pharmaceuticals Business Overview
        11.7.3 Meda Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.7.4 Meda Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.7.5 Meda Pharmaceuticals Recent Developments
    11.8 Cipla
        11.8.1 Cipla Company Details
        11.8.2 Cipla Business Overview
        11.8.3 Cipla Selective Cox-2 Inhibitors Introduction
        11.8.4 Cipla Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.8.5 Cipla Recent Developments
    11.9 Glenmark Pharmaceuticals
        11.9.1 Glenmark Pharmaceuticals Company Details
        11.9.2 Glenmark Pharmaceuticals Business Overview
        11.9.3 Glenmark Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.9.4 Glenmark Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.9.5 Glenmark Pharmaceuticals Recent Developments
    11.10 Teva
        11.10.1 Teva Company Details
        11.10.2 Teva Business Overview
        11.10.3 Teva Selective Cox-2 Inhibitors Introduction
        11.10.4 Teva Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.10.5 Teva Recent Developments
    11.11 PuraCap Pharmaceutical
        11.11.1 PuraCap Pharmaceutical Company Details
        11.11.2 PuraCap Pharmaceutical Business Overview
        11.11.3 PuraCap Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.11.4 PuraCap Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.11.5 PuraCap Pharmaceutical Recent Developments
    11.12 Almirall Limited
        11.12.1 Almirall Limited Company Details
        11.12.2 Almirall Limited Business Overview
        11.12.3 Almirall Limited Selective Cox-2 Inhibitors Introduction
        11.12.4 Almirall Limited Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.12.5 Almirall Limited Recent Developments
    11.13 Lupin Pharmaceuticals
        11.13.1 Lupin Pharmaceuticals Company Details
        11.13.2 Lupin Pharmaceuticals Business Overview
        11.13.3 Lupin Pharmaceuticals Selective Cox-2 Inhibitors Introduction
        11.13.4 Lupin Pharmaceuticals Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.13.5 Lupin Pharmaceuticals Recent Developments
    11.14 Aurobindo Pharma
        11.14.1 Aurobindo Pharma Company Details
        11.14.2 Aurobindo Pharma Business Overview
        11.14.3 Aurobindo Pharma Selective Cox-2 Inhibitors Introduction
        11.14.4 Aurobindo Pharma Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.14.5 Aurobindo Pharma Recent Developments
    11.15 Pfizer
        11.15.1 Pfizer Company Details
        11.15.2 Pfizer Business Overview
        11.15.3 Pfizer Selective Cox-2 Inhibitors Introduction
        11.15.4 Pfizer Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.15.5 Pfizer Recent Developments
    11.16 Mylan
        11.16.1 Mylan Company Details
        11.16.2 Mylan Business Overview
        11.16.3 Mylan Selective Cox-2 Inhibitors Introduction
        11.16.4 Mylan Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.16.5 Mylan Recent Developments
    11.17 Takeda
        11.17.1 Takeda Company Details
        11.17.2 Takeda Business Overview
        11.17.3 Takeda Selective Cox-2 Inhibitors Introduction
        11.17.4 Takeda Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.17.5 Takeda Recent Developments
    11.18 Bayer
        11.18.1 Bayer Company Details
        11.18.2 Bayer Business Overview
        11.18.3 Bayer Selective Cox-2 Inhibitors Introduction
        11.18.4 Bayer Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.18.5 Bayer Recent Developments
    11.19 Novacap
        11.19.1 Novacap Company Details
        11.19.2 Novacap Business Overview
        11.19.3 Novacap Selective Cox-2 Inhibitors Introduction
        11.19.4 Novacap Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.19.5 Novacap Recent Developments
    11.20 Abbott
        11.20.1 Abbott Company Details
        11.20.2 Abbott Business Overview
        11.20.3 Abbott Selective Cox-2 Inhibitors Introduction
        11.20.4 Abbott Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.20.5 Abbott Recent Developments
    11.21 Geri-Care
        11.21.1 Geri-Care Company Details
        11.21.2 Geri-Care Business Overview
        11.21.3 Geri-Care Selective Cox-2 Inhibitors Introduction
        11.21.4 Geri-Care Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.21.5 Geri-Care Recent Developments
    11.22 Perrigo
        11.22.1 Perrigo Company Details
        11.22.2 Perrigo Business Overview
        11.22.3 Perrigo Selective Cox-2 Inhibitors Introduction
        11.22.4 Perrigo Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.22.5 Perrigo Recent Developments
    11.23 Kopran
        11.23.1 Kopran Company Details
        11.23.2 Kopran Business Overview
        11.23.3 Kopran Selective Cox-2 Inhibitors Introduction
        11.23.4 Kopran Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.23.5 Kopran Recent Developments
    11.24 Merck
        11.24.1 Merck Company Details
        11.24.2 Merck Business Overview
        11.24.3 Merck Selective Cox-2 Inhibitors Introduction
        11.24.4 Merck Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.24.5 Merck Recent Developments
    11.25 Hengrui pharmaceutical
        11.25.1 Hengrui pharmaceutical Company Details
        11.25.2 Hengrui pharmaceutical Business Overview
        11.25.3 Hengrui pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.25.4 Hengrui pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.25.5 Hengrui pharmaceutical Recent Developments
    11.26 Kelun Group
        11.26.1 Kelun Group Company Details
        11.26.2 Kelun Group Business Overview
        11.26.3 Kelun Group Selective Cox-2 Inhibitors Introduction
        11.26.4 Kelun Group Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.26.5 Kelun Group Recent Developments
    11.27 Qilu Pharmaceutical
        11.27.1 Qilu Pharmaceutical Company Details
        11.27.2 Qilu Pharmaceutical Business Overview
        11.27.3 Qilu Pharmaceutical Selective Cox-2 Inhibitors Introduction
        11.27.4 Qilu Pharmaceutical Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.27.5 Qilu Pharmaceutical Recent Developments
    11.28 Taro Pharmaceuticals 
        11.28.1 Taro Pharmaceuticals  Company Details
        11.28.2 Taro Pharmaceuticals  Business Overview
        11.28.3 Taro Pharmaceuticals  Selective Cox-2 Inhibitors Introduction
        11.28.4 Taro Pharmaceuticals  Revenue in Selective Cox-2 Inhibitors Business (2017-2022)
        11.28.5 Taro Pharmaceuticals  Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
    13.1 Research Methodology
        13.1.1 Methodology/Research Approach
        13.1.2 Data Source
    13.2 Author Details
    13.3 Disclaimer                        

Research Methodology

Data collection and base year analysis are done using proprietary data collection modules with large sample sizes. The process includes obtaining market information through extensive secondary sources, paid databases, and verifying data via primary (industry expert) validation.

Our market models include Vendor Positioning Grids, Market Timeline Analysis, Company Market Share Analysis, and Top-Down/Bottom-Up forecasting models. To know more about the research methodology, drop an inquiry to speak to our industry experts.

Speak to Analyst

Global Selective Cox-2 Inhibitors Market